The introduction of esketamine nasal spray represents a potential change in the approach of treatment-resistant mood disorders across the EU . While until recently requiring hospital-based https://spravatoineurope160067.blogstival.com/64129374/copyright-a-innovative-treatment-a-new-hope-for-depression-in-european-countries